Comparative effectiveness of 2nd-line targeted therapies for metastatic renal cell carcinoma: analysis of two practice-based chart reviews
Survival following initiation of everolimus for 2nd-line treatment of metastatic renal cell carcinoma: prognostic factors in clinical practice and comparison to clinical trials
Association between guideline-adherent imaging and overall survival following 2nd-line targeted therapy for metastatic renal cell carcinoma
Contrast enhancement on CT following renal cryoablation – does it represent treatment failure?
The lifetime cost of everolimus vs. axitinib in metastatic renal cell carcinoma patients who have failed prior sunitinib therapy in the US
FGF-mediated angiogenesis as independent mechanism of resistance to VEGF / VEGFR targeting
A phase 3 randomized study of cabozantinib (XL184) vs everolimus in subjects with clear cell renal cell carcinoma (METEOR)
Sunitinib expanded-access trial in metastatic renal cell carcinoma (mRCC) – final US results
Multiplexed tissue protein assay as a predictor of response to targeted therapy in advanced renal cell carcinoma
Role of cytoreductive nephrectomy (CN) in patients with metastatic non-clear cell renal cell carcinoma (nccRCC): results from a surveillance, epidemiology, and end results (SEER) database analysis of over 4,900 patients
The initial experience with RENAL nephrometry in children, adolescents, and young adults with renal tumors
Quadrant biopsy technique improves diagnostic ability for large renal masses
Proposal of an algorithm for utilization of percutaneous renal mass biopsy based on the results of 1000 case series
Safety, durable clinical benefit, and remission resulting from nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase 1 trial in patients with previously treated metastatic renal cell carcinoma (mRCC); long-term patient follow-up
A phase 3 comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus everolimus in patients with advanced or metastatic renal cell carcinoma (mRCC) previously treated with anti-angiogenic therapy
Impact of bone metastases (BM) and bisphosphonate use in patients with metastatic renal cell carcinoma (mRCC) treated with targeted therapy: Results from a pooled clinical trials database
Combined low activity GSTA1 and active GSTT1 genotypes modify risk for renal cell carcinoma
ADAPT: An Ongoing international phase 3 randomized trial of autologous dendritic cell Immunotherapy (AGS 003) plus standard treatment in advanced renal cell carcinoma (RCC)
Hypoxia response regulates clear cell renal cell carcinoma tumor initiating cells
Chronic myeloid leukaemia development in the course of ccRCC treatment with tyrosine kinase inhibitors
Survival, safety and treatment response duration in “real world” patients with metastatic clear cell renal cancer – an update from clinical practice
Brain metastasis from renal cell carcinoma, are we missing our chance to treat?
Utilization of renal mass biopsy in patients with renal cell carcinoma
Nano-scale proteomic profiling to define diagnostic signatures and biomarkers of therapeutic activity in patients with RCC
Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era
Poorly functioning kidneys recover from ischemia during partial nephrectomy as well as strongly functioning kidneys